“Aviptadil proved effective for critical COVID-19 respiratory failure.”

Not established

The reviewed evidence does not establish this statement. This does not prove it can never be true.

The 196-person randomized trial did not meet its prespecified day-60 primary endpoint. Secondary and subgroup results cannot make the primary endpoint significant.

What this answer is based on

This answer uses a study that assigned people to groups by chance and measured a health outcome.

Limits of this answer

Intravenous aviptadil in the 2022 trial; no inference about another VIP product. These limits show which substance, product, people, use, place, and time the answer covers. A different product or situation can have a different answer.

Topic

What a study measured about people's health, symptoms, or ability to function.